Nanotechnology based platforms for survivin targeted drug discovery

Rasika M Samarasighe, Jessica Gibbons, Rupinder K Kanwar, Jagat R Kanwar

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Introduction: Development of an effective, safe and targeted drug delivery system to fight cancer and other diseases is a prime focus in the area of drug discovery. The emerging field of nanotechnology has revolutionised the way cancer therapy and diagnosis is achieved primarily due to the recent advances in material engineering and drug availability. Further, the recognition of the crucial role played by anti-apoptotic proteins such as survivin, has initiated the development of therapeutics that can target this protein as an attempt to develop alternative cancer therapies. However, a key challenge faced in drug development is the efficient delivery of survivin-targeted molecules to specific areas in the body. Areas covered: This review primarily focuses on the different strategies employing nanotechnology for targeting survivin expressed in human cancers. Different nanomaterials incorporating nucleic molecules or drugs targeted at survivin are discussed and the results obtained from studies are highlighted. Expert opinion: There are extensive studies reporting different treatment regimens for cancer, however, they still result in systemic toxicity, reduced bioavailability and ineffective delivery. Novel approaches involve the use of biocompatible nanomaterials together with gene or drug molecules to target proteins such as survivin, which is overexpressed in cancerous cells. These nanoformulations allow the benefits of protecting easily degradable molecules, allow controlled release, and enhance targeted delivery and effectiveness. Hence, nanotherapy utilizing survivin targeting can be considered to play a key role in the development of personalized nanomedicine for cancer. 

Original languageEnglish
Pages (from-to)1083-1092
Number of pages10
JournalExpert Opinion on Drug Discovery
Volume7
Issue number11
DOIs
Publication statusPublished - 5 Sep 2012
Externally publishedYes

Keywords

  • Cancer
  • Liposomes
  • Nanotherapy
  • Polymeric
  • Survivin

Cite this

Samarasighe, Rasika M ; Gibbons, Jessica ; Kanwar, Rupinder K ; Kanwar, Jagat R. / Nanotechnology based platforms for survivin targeted drug discovery. In: Expert Opinion on Drug Discovery. 2012 ; Vol. 7, No. 11. pp. 1083-1092.
@article{240028f76eaa4e56abc4a717b91d6a90,
title = "Nanotechnology based platforms for survivin targeted drug discovery",
abstract = "Introduction: Development of an effective, safe and targeted drug delivery system to fight cancer and other diseases is a prime focus in the area of drug discovery. The emerging field of nanotechnology has revolutionised the way cancer therapy and diagnosis is achieved primarily due to the recent advances in material engineering and drug availability. Further, the recognition of the crucial role played by anti-apoptotic proteins such as survivin, has initiated the development of therapeutics that can target this protein as an attempt to develop alternative cancer therapies. However, a key challenge faced in drug development is the efficient delivery of survivin-targeted molecules to specific areas in the body. Areas covered: This review primarily focuses on the different strategies employing nanotechnology for targeting survivin expressed in human cancers. Different nanomaterials incorporating nucleic molecules or drugs targeted at survivin are discussed and the results obtained from studies are highlighted. Expert opinion: There are extensive studies reporting different treatment regimens for cancer, however, they still result in systemic toxicity, reduced bioavailability and ineffective delivery. Novel approaches involve the use of biocompatible nanomaterials together with gene or drug molecules to target proteins such as survivin, which is overexpressed in cancerous cells. These nanoformulations allow the benefits of protecting easily degradable molecules, allow controlled release, and enhance targeted delivery and effectiveness. Hence, nanotherapy utilizing survivin targeting can be considered to play a key role in the development of personalized nanomedicine for cancer. ",
keywords = "Cancer, Liposomes, Nanotherapy, Polymeric, Survivin",
author = "Samarasighe, {Rasika M} and Jessica Gibbons and Kanwar, {Rupinder K} and Kanwar, {Jagat R}",
year = "2012",
month = "9",
day = "5",
doi = "10.1517/17460441.2012.719869",
language = "English",
volume = "7",
pages = "1083--1092",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Taylor & Francis",
number = "11",

}

Nanotechnology based platforms for survivin targeted drug discovery. / Samarasighe, Rasika M; Gibbons, Jessica; Kanwar, Rupinder K; Kanwar, Jagat R.

In: Expert Opinion on Drug Discovery, Vol. 7, No. 11, 05.09.2012, p. 1083-1092.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Nanotechnology based platforms for survivin targeted drug discovery

AU - Samarasighe, Rasika M

AU - Gibbons, Jessica

AU - Kanwar, Rupinder K

AU - Kanwar, Jagat R

PY - 2012/9/5

Y1 - 2012/9/5

N2 - Introduction: Development of an effective, safe and targeted drug delivery system to fight cancer and other diseases is a prime focus in the area of drug discovery. The emerging field of nanotechnology has revolutionised the way cancer therapy and diagnosis is achieved primarily due to the recent advances in material engineering and drug availability. Further, the recognition of the crucial role played by anti-apoptotic proteins such as survivin, has initiated the development of therapeutics that can target this protein as an attempt to develop alternative cancer therapies. However, a key challenge faced in drug development is the efficient delivery of survivin-targeted molecules to specific areas in the body. Areas covered: This review primarily focuses on the different strategies employing nanotechnology for targeting survivin expressed in human cancers. Different nanomaterials incorporating nucleic molecules or drugs targeted at survivin are discussed and the results obtained from studies are highlighted. Expert opinion: There are extensive studies reporting different treatment regimens for cancer, however, they still result in systemic toxicity, reduced bioavailability and ineffective delivery. Novel approaches involve the use of biocompatible nanomaterials together with gene or drug molecules to target proteins such as survivin, which is overexpressed in cancerous cells. These nanoformulations allow the benefits of protecting easily degradable molecules, allow controlled release, and enhance targeted delivery and effectiveness. Hence, nanotherapy utilizing survivin targeting can be considered to play a key role in the development of personalized nanomedicine for cancer. 

AB - Introduction: Development of an effective, safe and targeted drug delivery system to fight cancer and other diseases is a prime focus in the area of drug discovery. The emerging field of nanotechnology has revolutionised the way cancer therapy and diagnosis is achieved primarily due to the recent advances in material engineering and drug availability. Further, the recognition of the crucial role played by anti-apoptotic proteins such as survivin, has initiated the development of therapeutics that can target this protein as an attempt to develop alternative cancer therapies. However, a key challenge faced in drug development is the efficient delivery of survivin-targeted molecules to specific areas in the body. Areas covered: This review primarily focuses on the different strategies employing nanotechnology for targeting survivin expressed in human cancers. Different nanomaterials incorporating nucleic molecules or drugs targeted at survivin are discussed and the results obtained from studies are highlighted. Expert opinion: There are extensive studies reporting different treatment regimens for cancer, however, they still result in systemic toxicity, reduced bioavailability and ineffective delivery. Novel approaches involve the use of biocompatible nanomaterials together with gene or drug molecules to target proteins such as survivin, which is overexpressed in cancerous cells. These nanoformulations allow the benefits of protecting easily degradable molecules, allow controlled release, and enhance targeted delivery and effectiveness. Hence, nanotherapy utilizing survivin targeting can be considered to play a key role in the development of personalized nanomedicine for cancer. 

KW - Cancer

KW - Liposomes

KW - Nanotherapy

KW - Polymeric

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=84867957622&partnerID=8YFLogxK

U2 - 10.1517/17460441.2012.719869

DO - 10.1517/17460441.2012.719869

M3 - Review Article

VL - 7

SP - 1083

EP - 1092

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 11

ER -